The case for & against
Bull & Bear analysis
Bullish
Evotec SE (NASDAQ: EVO) is a prominent player in the biotechnology sector, specializing in drug discovery and development partnerships, particularly within the fields of biologics and integrated drug development. The company operates two main segments: Discovery and Preclinical Development (DMPD) and Just Evotec Biologics (JEB). Positioned strategically amid market demands, Evotec leverages strong scientific capabilities to address the evolving needs of its pharmaceutical partners while navigating complex funding dynamics in the biotech landscape.
Bull says
- ↑JEB revenue up 104.2% YoY in Q4 2025, with €259.4M forecast for 2025
- ↑Horizon transformation to drive ~€75M in annual cost savings by 2027
- ↑DMPD net sales increased 28%, indicating stronger customer engagement
- ↑AI integration in drug discovery platforms boosts competitive positioning
- ↑€476M cash liquidity provides a robust financial cushion
- ↑Undervalued book-to-price ratio suggests potential upside
Bear says
- ↓DMPD revenues declined 12% YoY, reflecting ongoing early-stage softness
- ↓Reliance on Bristol-Myers Squibb partnership risks payment delays and underperformance
- ↓Negative earnings yield and high volatility signal return and price fluctuation risks
- ↓€13M FX headwind pressures revenue realization
- ↓Execution risks in asset-light Horizon shift could derail expected savings
- ↓Weak profitability revisions and high leverage heighten financial risk
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 09-13-2026bullish
Transcript signals
Bull points
- JustEvaTech Biologics has continued to grow strongly in the first half of 2025, reaching 102.2 million euros of revenue, which is up 16% versus the first half of 2024. The majority of the year-on-year growth is driven by the excellent growth of our business with non-Sandoz and DoD customers as we broaden our customer base.
- 87% growth versus prior year, underlining our very positive outlook for the Just Evotech Biologics business.
- Our cost out initiatives are progressing well. With the initial target for the discipline spending and hiring activities already being reached, and external spend management progressing as expected.
Bear points
- 371 million euros, a 5% decrease versus the first half of 2024, which has been impacted by two counterbalancing effects. Firstly, our D&PD revenues declined by 11% to 269 million euros in a persisting soft market as Christian alluded to during his introduction.
- Adjusted Group EBITDA reached negative 1.9 million euros driven by stronger than expected contribution of seven and a half million euros from the Just Evotech Biologics business, helped by positive operating leverage, despite the just organization build out that we articulated in our April call.
- H1 has not been without its challenges. we saw a revenue decline in our discovery and preclinical development segment of 11%. A large part of that is related to a temporary effect in our BMS collaboration. The remainder is driven by continued softness in the early drug discovery market.
Read full transcript analysis ›